KO4/9/6 510(k)

JUL 3 0 2004

Section 4.2.13b

510(k) Summary of S&E

(Immediately follows this page)

Date: 6/8/04

510(k) Summary: Aloka Model SSD- Alpha 5

This summary statement complies with 21 CFR, section 807.92 as amended March 14, 1995.

This premarket notification has been submitted by Aloka Co., Ltd. and covers the Aloka SSD-Alpha 5 Ver.1.0 diagnostic ultrasound system and transducers.

The address is:

10 Fairfield Boulevard Wallingford, CT 06492 (203) 269-5088

The contact person is: Richard J. Cehovsky, RA/QA Coordinator

The proprietary name is the Aloka SSD-Alpha 5 diagnostic ultrasound system and transducers. The common name for this type of device is a diagnostic ultrasound system and transducers.

The item in this submission is covered under the following classification:

90 IYN	Ultrasonic Pulsed Doppler Imaging System	21 CFR 892.1550
90 ITX	Diagnostic Ultrasound Transducer	21 CFR 892.1570
90 IYO	Ultrasonic Pulsed Echo Imaging System.	21 CFR 892.1560

The above as stated in 21CFR, part 892.1570,1560 & 1550, has been classified as regulatory Class II.

The Aloka SSD- Alpha 5 and its transducers are substantially equivalent to its predicate; the Aloka SSD-5500 (K032875) and its transducers.

The Aloka SSD-Alpha 5 functions in the same manner as its predicate and other Aloka diagnostic ultrasound devices. High frequency sound waves are transmitted into the body by a piezo-electric transducer. In the body, differences in the acoustic impedance of different tissues reflect a certain amount of the ultrasound energy back to the transducer, where it is transmitted via the probe cable to the system console and processed into an image. The Aloka SSD-Alpha 5 transducers can also use the Doppler shift of sound reflected from moving tissues (blood) to detect and display flow.

The Aloka SSD-Alpha 5, like other Aloka marketed diagnostic ultrasound systems and transducers are indicated for imaging body structures to aid in the diagnosis of disease or abnormality.

The Aloka SSD-Alpha 5 diagnostic ultrasound system and transducers are similar in technological characteristics to its predicate system: SSD-5500 (K032875).

- The Aloka SSD-Alpha 5 is indicated for the same diagnostic ultrasound applications to Aloka's ultrasound system: SSD-5500 (K032875).
- The Aloka SSD-Alpha 5 has the same gray-scale and Doppler abilities to Aloka's ultrasound system as mentioned above.

510(k) Summary: Aloka Model SSD- Alpha 5

- The SSD-Alpha 5 uses the same technologies for imaging, Doppler functions and signal processing as the following product currently marketed by Aloka: SSD-5500 (K032875).
- The SSD-Alpha 5 has the same method of use as the following product currently marketed by Aloka: SSD-5500 (K032875).
- The SSD-Alpha 5 acoustic power output levels are below the maximum levels allowed by the FDA.
- The SSD- Alpha 5 is subjected to the same Quality Assurance systems in development and production as other products including the SSD-5500 (K032875) currently marketed by Aloka.
- The patient contact materials used in the SSD-Alpha 5 have been evaluated for safety via the same standards and methods as the above mentioned product marketed by Aloka. These materials have been found to be safe for their intended uses.
- The SSD-Alpha 5 complies with electrical and physical safety standards as other products currently marketed by Aloka such as the: SSD-5500 (K032875).
- Aloka Co., Ltd. Certifies that the SSD-Alpha 5 complies with NEMA-UD2: 1992, AIUM 1994
 "Acoustic Output Labeling Standard for Diagnostic Ultrasound Equipment", IEC-60601-1 (2001-09 Class A), UL 2601-1, 2nd edition (1997), Part 1, 2nd edition including Amendments 1&2 and ISO10993-1:1997. All testing will be completed, prior to distribution, to meet the requirements of the standards listed above.



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 3 0 2004

Aloka Co., Ltd. % Mr. Daniel W. Lehtonen Staff Engineer - Medical Devices Intertek Testing Services NA, Inc. 70 Codman Hill Road BOXBOROUGH MA 01719

Re: K041916

Trade Name: Aloka SSD-Alpha 5 Ultrasound System

Regulation Number: 21 CFR §892.1550

Regulation Name: Ultrasonic pulsed doppler imaging system

Regulation Number: 21 CFR §892.1560

Regulation Name: Ultrasonic pulsed echo imaging system

Regulation Number: 21 CFR §892.1570

Regulation Name: Diagnostic ultrasonic transducer

Regulatory Class: II

Product Code: 90 IYN, IYO, and ITX

Dated: July 15, 2004 Received: July 16, 2004

Dear Mr. Lehtonen:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

This determination of substantial equivalence applies to the following transducers intended for use with the Aloka SSD-Alpha 5 Ultrasound System, as described in your premarket notification:

Transducer Model Number

UST-5410	<u>UST-9128</u>
UST-9118	<u>UST-52101</u>
UST-9126	<u>UST-52108</u>

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.

The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:

Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850

This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801, please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".

Page 3 - Mr. Lehtonen

If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.

Sincerely yours,

Mancy C. Brogdon
Director, Division of Reproductive, Abdominal and Radiological Devices

Office of Device Evaluation

Center for Devices and Radiological Health

Enclosures

4.3.1

Diagnostic Ultrasound Indications for Use Form SSD-Alpha 5

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic		-										
Fetal		N	N	N	N	N	N		See Below			
Abdominal		N	N	N	N	N	N		See Below			
Intraoperative (specify)												
Intraoperative Neurological			<u> </u>									
Pediatric		N	N	N	N	N	N		See Below			
Small Organ (specify)		N	N	N	N	N	N		See Below			
Neonatal Cephalic		N	N	N	N	N	N		See Below			
Adult Cephalic		 	 									
Cardiac		N	N	N	N	N	N	- "	See Below			
Transesophageal			_									
Transrectal									1			
Transvaginal		N	N	N	N	N	N		See Below			
Transurethral												
Intravascular	 			<u> </u>	1							
Peripheral Vascular		N	N	N	N	N	N		See Below			
Laparoscopic							<u> </u>					
Musculo-skeletal Conventional					1							
Musculo-skeletal Superficial		N	N	N	N	N	N		See Below			
Other												

N= new indication; P= previously cleared by FDA; E= added under Appendix A

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD Applications: Small Parts-breast, testes & thyroid, abdominal, gynecological, fetal, neonatal, cardiac.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal, and Radiological Devices

510(k) Number.

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic				<u> </u>								
Fetal					_							
Abdominal												
Intraoperative (specify)												
Intraoperative Neurological		-										
Pediatric												
Small Organ (specify)		N	N	N	N	N	N		See Below			
Neonatal Cephalic							1			-		
Adult Cephalic												
Cardiac		-										
Transesophageal		 										
Transrectal	 	<u> </u>		 						_		
Transvaginal			 		<u> </u>		 					
Transurethral										· · · · · · · · · · · · · · · · · · ·		
Intravascular		 	 		-							
Peripheral Vascular		N	N	N	N	N	N		See Below			
Laparoscopic	 				 							
Musculo-skeletal Conventional												
Musculo-skeletal Superficial		N	N	N	N	N	N		See Below			
Other												

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD

Applications: breast, testes and thyroid.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use (Per 21 CFR 801 109)

(Division Sign-Off)	()
Division of Reproductive,	Abdominal,
and Padiological Devices	10./

510(k) Number _

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

<u> </u>	Modes of operation											
Clinical Application	A	В	M	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic	-									<u>.</u>		
Fetal	-	P	P	P	P	P	Р		See Below			
Abdominal												
Intraoperative (specify)												
Intraoperative Neurological			-	<u> </u>								
Pediatric												
Small Organ (specify)												
Neonatal Cephalic	-							<u> </u>				
Adult Cephalic												
Cardiac												
Transesophageal			1		-							
Transrectal					-							
Transvaginal		P	P	P	P	P	P		See Below			
Transurethral	<u> </u>		1									
Intravascular		†	ļ							<u> </u>		
Peripheral Vascular								***				
Laparoscopic			†				1		-			
Musculo-skeletal Conventional												
Musculo-skeletal Superficial												
Other	1						1					

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices
510(k) Number

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic												
Fetal		P	P	P	Р	P	Р		See Below			
Abdominal		P	P	P	P	P	P		See Below			
Intraoperative (specify)												
Intraoperative Neurological												
Pediatric		1			1							
Small Organ (specify)												
Neonatal Cephalic												
Adult Cephalic												
Cardiac									•			
Transesophageal		†	-									
Transrectal												
Transvaginal												
Transurethral		 	1				"					
Intravascular		<u> </u>	 									
Peripheral Vascular		1										
Laparoscopic												
Musculo-skeletal Conventional												
Musculo-skeletal Superficial			1									
Other			1									

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD.

Applications: Abdominal, Gynecological, Fetal.

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number.

22

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic												
Fetal												
Abdominal		P	P	Р	P	P	P		See Below			
Intraoperative (specify)					-							
Intraoperative Neurological												
Pediatric		P	P	P	P	Р	P		See Below	<u> </u>		
Small Organ (specify)	-											
Neonatal Cephalic							-					
Adult Cephalic		1	 									
Cardiac			+									
Transesophageal	-	1	1					-				
Transrectal		 	1-		<u> </u>				-			
Transvaginal	 	 										
Transurethral	 	 		-								
Intravascular			 	 					-			
Peripheral Vascular		 			_					_		
Laparoscopic		 			 							
Musculo-skeletal Conventional	-	-										
Musculo-skeletal Superficial												
Other		1										

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801 109)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices
510(k) Number

23

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic		1										
Fetal												
Abdominal			<u> </u>									
Intraoperative (specify)	-	<u> </u>										
Intraoperative Neurological		<u> </u>										
Pediatric		1	1									
Small Organ (specify)		1										
Neonatal Cephalic		† — ·	1									
Adult Cephalic												
Cardiac		P	P	P	P	P	P		See Below			
Transesophageal												
Transrectal		<u> </u>	 									
Transvaginal		 	 		<u> </u>							
Transurethral		1										
Intravascular			<u> </u>			1						
Peripheral Vascular												
Laparoscopic	-											
Musculo-skeletal Conventional Musculo-skeletal			_									
Superficial		<u> </u>	<u> </u>									
Other	_								<u></u>	<u> </u>		

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)
Division of Reproductive, Abdominal, and Radiological Devices

510(k) Number _

Intended Use: Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:

	Modes of operation											
Clinical Application	A	В	М	PWD	CWD	Color Doppler	Amplitude Doppler	Color Velocity Imaging	Combined (specify)	Other (specify)		
Opthalmic	-											
Fetal		-										
Abdominal												
Intraoperative (specify)					i i							
Intraoperative Neurological		·							<u> </u>			
Pediatric									<u> </u>	ļ <u>.</u>		
Small Organ (specify)												
Neonatal Cephalic		P	P	Р	P	P	P		See Below			
Adult Cephalic	ļ											
Cardiac		Р	P	P	P	P	P		See Below			
Transesophageal												
Transrectal												
Transvaginal			T									
Transurethral												
Intravascular												
Peripheral Vascular												
Laparoscopic												
Musculo-skeletal Conventional Musculo-skeletal		-										
Superficial	<u> </u>	ļ					<u> </u>	-				
Other			-					<u> </u>		<u> </u>		

N= new indication; P= previously cleared by FDA; E= added under Appendix E

Additional Comments: Mixed mode operation includes B/M, B/PWD, M/CD, B/CD/PWD, B/CWD, B/CD/CWD

Application: Neonatal

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Per 21 CFR 801.109)

(Division Sign-Off)

Division of Reproductive, Abdominal,

and Radiological Devices

510(k) Number ...